Disarming bacteria: A novel approach to treating bacterial infections?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Disarming bacteria: A novel approach to treating bacterial infections?
Released on: July 12, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    QureTech Bio is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens.
  • Summary
  • Transcript
  • Participants
  • Company
QureTech Bio is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens. Termed virulence blockers. Dr Fritiof Pontén discusses with Adrian Dawkes how these agents selectively disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora, and therefore decrease the selection pressure for resistance development.
QureTech Bio is developing a new class of antibacterial agents that may have broad-spectrum activity against Chlamydia and other pathogens. Termed virulence blockers. Dr Fritiof Pontén discusses with Adrian Dawkes how these agents selectively disarm the pathogenic capability of certain bacteria, without affecting normal bacterial flora, and therefore decrease the selection pressure for resistance development.
Dr. Fritiof Pontén has a solid experience of drug development gathered during 17 years at AstraZeneca. He has been active in a wide range of drug project activities ranging from all discovery phases to late stage preclinical studies enabling First Time in Man. Besides his work in drug projects Fritiof has been active within organizational and technical development. He has built up and headed a facility and organisation for scale up of drug candidates from mg to kg during the last 10 years. Fritiof has grown his team from scratch and introduced novel capabilities such as continuous processing, bio-catalysis and asymmetric catalysis in the daily deliveries. In his role as Senior Scientist and later Associate Principle Scientist Fritiof was active in drug projects ranging from early Lead Discovery to late stage Lead Optimization. He introduced multi parallell synthesis in combination with a scaffold hopping within a antiarrythmia lead optimization project. This resulted in the invention of AZD7009 and AZD1305, the first two fully non-proarrythmic oral drugs that went into man.
Since World War II, antibiotics have been the most effective factor in longevity and population expansion. Today, loss of effective antibiotics threatens our medical institutions – antibiotic resistance is a serious problem already or will be within the decade. Doctors, in the US and UK, have reported that they now have less than a handful effective antibiotics for some pathogens. In the EU alone, infections with multidrug resistant bacteria cause around 25,000 deaths each year and the associated economic burden is immense. Still in today’s world, more infants and children are dying from pneumonia than from malaria. QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems. New types of antibiotics to tackle resistant bacteria are urgently needed, yet there is an almost empty drug pipeline with few early stage drugs under development. Scientific and industrial communities must develop new antibiotic drugs, and there must be a drive towards developing novel antibiotics with alternative modes of action.